Pharma industry invests £381m in UK R&D activities

The pharmaceutical industry has invested £381.2 million on R&D activities in the UK during 2019, up from £377.3 million in 2018, according to new data published on Disclosure UK.

Disclosure UK is the public, pharmaceutical industry-led database which details aggregate R&D spend, as well as individual payments and benefits in kind made to UK healthcare professionals (HCPs) and healthcare organisations (HCOs).

Last month, the Association of the British Pharmaceutical Industry (ABPI) announced it would be publishing 2019 data in a way which minimises any pressure on NHS workers, hospitals and other NHS organisations as they respond to the COVID-19 pandemic.

This means that some of the 2019 data is not broken down by individual HCPs and HCOs as usual. This was a temporary change because of the pandemic, and the ABPI plans to republish the usual, more detailed data as soon as possible.

The available 2019 figures show:

  • £538.2 million has been disclosed by pharmaceutical companies for 2019, compared with £503million in 2018 (excluding joint-working).
  • £381.2 million of this was spent on R&D, compared with £377.3 million in 2018
  • £157 million of this was spent on non-R&D collaborations with HCPs and HCOs in 2019, vs £125.7 million in 2018 (excluding joint-working). Much of this increase was due to payments to healthcare organisations.
  • 11 new companies have disclosed payments this year, bringing the total number of companies using Disclosure UK to 143.

“The 2019 disclosure data available so far tells a hugely positive story – the third successive year of increasing investment by industry in UK R&D. This can only be a good thing for patients and the NHS,” said Richard Torbett, Chief Executive of the ABPI.

“We will publish the normal breakdown of disclosure data as soon as we are able, and when we do, it should also help us understand more about how the data has changed over time.

“We’re proud of the work we do with the NHS, without which the development of new medicines and vaccines would be impossible, and will continue strive for the highest levels of openness and transparency in the relationships between industry and healthcare professionals.”

A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site but journalism costs money and we rely on advertising and digital revenues to help to support them.

With the Covid-19 lockdown having a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites with a small donation of even £1, your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

In the meantime may I wish you the very best.

- Advertisement -

Blenrep becomes first anti-BCMA approved globally

GlaxoSmithKline (GSK) has secured US approval for Blenrep (belantamab mafodotin-blmf) as a monotherapy treatment for adult patients with relapsed or refractory multiple myeloma. This indication...

Joint investment sees UK gov secure pipeline of coronavirus vaccine candidate

The UK government and biotech Valneva have jointly invested in a Scottish facility to bolster vaccine manufacturing capacity. The multi-million-pound investment will allow the government...

Redx out-licenses porcupine inhibitor to AstraZeneca

UK drug discovery and development company, Redx Pharma, has signed a significant out-licensing agreement for its porcupine inhibitor, RXC006, with AstraZeneca. AstraZeneca will take RXC006...

New Chief Medical Officer for Valneva

Valneva, a specialty vaccine company based in France, has appointed Juan Carlos Jaramillo, as Chief Medical Officer and member of the Management Board. Starting 1st...

Majority of top pharma firms report YoY growth in 2019 – data

In 2019, 17 of the top twenty major pharmaceutical players reported year-on-year revenue growth, according to GlobalData. “One winner was Takeda, which saw more than...

Related news

ACG promotes Susheel Pillai as the new CEO for Inspection Business

ACG, a leading supplier of fully integrated solutions to the global pharmaceutical and nutraceutical industry, today announced the promotion of Susheel Pillai as the new...

Blenrep becomes first anti-BCMA approved globally

GlaxoSmithKline (GSK) has secured US approval for Blenrep (belantamab mafodotin-blmf) as a monotherapy treatment for adult patients with relapsed or refractory multiple myeloma. This indication...

Joint investment sees UK gov secure pipeline of coronavirus vaccine candidate

The UK government and biotech Valneva have jointly invested in a Scottish facility to bolster vaccine manufacturing capacity. The multi-million-pound investment will allow the government...

Redx out-licenses porcupine inhibitor to AstraZeneca

UK drug discovery and development company, Redx Pharma, has signed a significant out-licensing agreement for its porcupine inhibitor, RXC006, with AstraZeneca. AstraZeneca will take RXC006...